Potential Leptin Receptor Response Modifier Peptides

Drug targets for the treatment of obesity and comorbidities represent an ever-renewable source of research opportunities worldwide. One of the earliest is the leptin–leptin receptor system that was discovered in the mid-1990s. Leptin, a satiety hormone, is overproduced in overweight patients but the...

Full description

Saved in:
Bibliographic Details
Published in:Critical studies in media communication 2020-01, Vol.73 (4), p.264
Main Author: OtvosJr, Laszlo
Format: Article
Language:English
Subjects:
Binding sites
Blood circulation
Blood-brain barrier
Brain research
Controllability
Design
Diabetes
FDA approval
Food
Mutation
Obesity
Peptides
Proteins
Receptors
Side effects
Signal transduction
Weight control
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug targets for the treatment of obesity and comorbidities represent an ever-renewable source of research opportunities worldwide. One of the earliest is the leptin–leptin receptor system that was discovered in the mid-1990s. Leptin, a satiety hormone, is overproduced in overweight patients but the protein is unable to cross the blood–brain barrier and remains inactive. Circulating high levels of leptin induces a series of conditions that would not be manifested without leptin overproduction, including various forms of cancer and inflammatory and cardiovascular diseases. Current pharmaceutical research focuses on improving the blood–brain barrier penetration of leptin receptor agonists and the development of monofunctional antagonists with broad spectrum therapeutic efficacies but without unwanted side effects. Designer peptides with their expanded chemical space as well as well controllable receptor binding and elimination properties slowly replace full-sized leptin products in the drug development pipeline.
ISSN:1529-5036
DOI:10.1071/CH19407